Set a bug to kill a bug
By Marian Turner,
Nature News
| 08. 16. 2011
Engineered bacteria that can detect and kill human pathogens could provide a new way to treat antibiotic-resistant bacteria. Using the tools of synthetic biology, researchers have given bacteria therapeutic properties unseen in any natural strain — although they won't be injected into people any time soon.
"Our study is the first example of how synthetic biology will be useful for fighting bacterial infections," says biochemical engineer Matthew Chang, an author on the paper, which is published today in Molecular Systems Biology.1
Chang and his team at Nanyang Technological University in Singapore have engineered a strain of Escherichia coli bacteria that attacks Pseudomonas aeruginosa, a bacterium that can cause lethal infections.
Pseudomonas aeruginosa competes with its own species by producing toxic proteins called pyocins. Chang's team exploited this molecular system by giving E. coli the genes for pyocin S5, which kills strains of P. aeruginosa that infect people. Because each pyocin targets only certain bacterial strains, the toxin will not kill other bacteria living in the body.
"Pyocins are the Pseudomonas bacterium's own species-specific antibiotics, so using pyocins...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...
